The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Update on the MELT-MM study: mezigdomide plus elranatamab in R/R MM
Ja Min Byun, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, shares an update on the MELT-MM study (NCT06645678), a two-part trial investigating the combination of mezigdomide and elranatamab for relapsed/refractory multiple myeloma (R/R MM). Dr Min Byun highlights that the Phase Ib results demonstrate favorable efficacy outcomes and a manageable safety profile. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
